These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recent insights into the mechanism of action of glatiramer acetate. Kala M; Miravalle A; Vollmer T J Neuroimmunol; 2011 Jun; 235(1-2):9-17. PubMed ID: 21402415 [TBL] [Abstract][Full Text] [Related]
4. The use of glatiramer acetate in the treatment of multiple sclerosis. Wolinsky JS Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839 [TBL] [Abstract][Full Text] [Related]
7. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis. Prescrire Int; 2009 Dec; 18(104):252. PubMed ID: 20025092 [No Abstract] [Full Text] [Related]
8. Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1. Teitelbaum D; Arnon R; Sela M Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3842-7. PubMed ID: 10097125 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Weber MS; Hohlfeld R; Zamvil SS Neurotherapeutics; 2007 Oct; 4(4):647-53. PubMed ID: 17920545 [TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate in the treatment of multiple sclerosis. Sela M; Teitelbaum D Expert Opin Pharmacother; 2001 Jul; 2(7):1149-65. PubMed ID: 11583066 [TBL] [Abstract][Full Text] [Related]
11. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260 [TBL] [Abstract][Full Text] [Related]
12. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration. Flechter S; Kott E; Steiner-Birmanns B; Nisipeanu P; Korczyn AD Clin Neuropharmacol; 2002; 25(1):11-5. PubMed ID: 11852290 [TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: modulation of apoptosis susceptibility by glatiramer acetate. Aktas O; Ari N; Rieks M; Hoffmann V; Schimrigk S; Przuntek H; Pöhlau D Acta Neurol Scand; 2001 Nov; 104(5):266-70. PubMed ID: 11696019 [TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Ragheb S; Abramczyk S; Lisak D; Lisak R Mult Scler; 2001 Feb; 7(1):43-7. PubMed ID: 11321193 [TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Farina C; Weber MS; Meinl E; Wekerle H; Hohlfeld R Lancet Neurol; 2005 Sep; 4(9):567-75. PubMed ID: 16109363 [TBL] [Abstract][Full Text] [Related]
16. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659 [TBL] [Abstract][Full Text] [Related]
17. Extended use of glatiramer acetate (Copaxone) for MS. Greenstein JI Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765 [No Abstract] [Full Text] [Related]
18. Copolymer-1 in the treatment of multiple sclerosis. Boyden KM J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622 [TBL] [Abstract][Full Text] [Related]
19. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M; Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077 [TBL] [Abstract][Full Text] [Related]
20. Copolymer 1: from basic research to clinical application. Teitelbaum D; Arnon R; Sela M Cell Mol Life Sci; 1997 Jan; 53(1):24-8. PubMed ID: 9117994 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]